FSE

Converge Reports Third Quarter 2023 Results

Retrieved on: 
Tuesday, November 14, 2023
OTCQX, FSE, AI, TSX, CTS, Converge, Beauty salon, Video game, Cryptocurrency, QC

TORONTO and GATINEAU, QC, Nov. 14, 2023 /PRNewswire/ -- Converge Technology Solutions Corp. ("Converge" or "the Company") (TSX: CTS) (FSE: 0ZB) (OTCQX: CTSDF) is pleased to provide its financial results for the three and nine months period ended September 30, 2023.  All figures are in Canadian dollars unless otherwise stated.

Key Points: 
  • TORONTO and GATINEAU, QC, Nov. 14, 2023 /PRNewswire/ -- Converge Technology Solutions Corp. ("Converge" or "the Company") (TSX: CTS) (FSE: 0ZB) (OTCQX: CTSDF) is pleased to provide its financial results for the three and nine months period ended September 30, 2023.
  • All figures are in Canadian dollars unless otherwise stated.
  • "The structural demand tailwinds of planning, implementing and monitoring complex technology projects whether AI, cloud or cyber related are driving a higher quality revenue mix," said Shaun Maine, Group CEO.
  • "Converge continues to witness significant demand for higher end products, services and solutions which is crucial to positioning the Company as a trusted advisor to our clients."

Patriot Drills Widest Mineralized Pegmatite Intersection to Date at the Corvette Property, Quebec, Canada

Retrieved on: 
Monday, November 13, 2023
FSE, Wildfire, Property, Quality assurance, The Company, CV13, ASX, CV5, Laboratory, Trans-Taiga Road, Patriot, Val-d'Or, Hydrogeology, Atmosphere, CV9, Pegmatite, Lithium, Pulverized coal injection method, News, Fire, Road, Rare-earth element, QC

Blair Way, Company Director, President, and CEO, comments: "The Corvette Property continues to deliver, with our widest intercept to date.

Key Points: 
  • Blair Way, Company Director, President, and CEO, comments: "The Corvette Property continues to deliver, with our widest intercept to date.
  • Returned core sample assays indicating wide and high-grade pegmatite intercepts continue to be returned at CV5.
  • We would also like to thank our shareholders for their patience with reporting of analytical results this summer-fall.
  • The 172.4 m intersection is comprised of a near-continuous pegmatite interval with only 1.8 m of non-pegmatite dilution.

EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million

Retrieved on: 
Thursday, December 14, 2023
XETRA, Financial services, Ruxolitinib, Relevance (Person of Interest), Frankfurt Stock Exchange, Regulation, Person, FSE, Wells Fargo, AMERICA, Qualification, Gross metropolitan product, Prospectus, Investment, EUR, Failure, MorphoSys, UBS, SEC Rule 144A, European Parliament, European Economic Area, Finance, BET, Council, Truist, Jefferies, Acquisition, EEA, Security (finance), Pharmaceutical industry, Order

The 3,423,194 new ordinary bearer shares with no-par value (Stückaktien) (“New Shares”) have been placed with institutional investors at a placement price of EUR 30.00 per new share by way of an accelerated bookbuilding, resulting in gross proceeds of approximately EUR 102.7 million.

Key Points: 
  • The 3,423,194 new ordinary bearer shares with no-par value (Stückaktien) (“New Shares”) have been placed with institutional investors at a placement price of EUR 30.00 per new share by way of an accelerated bookbuilding, resulting in gross proceeds of approximately EUR 102.7 million.
  • “MorphoSys’ oncology pipeline offers promising value-creating opportunities, with pelabresib, our investigational BET inhibitor, at the forefront,” said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys.
  • “With pelabresib, we have the potential to shift the treatment paradigm in myelofibrosis, a field in dire need of innovation.
  • The placement price represents a discount of 2.8% compared to the 5-day volume-weighted average price (XETRA) of the Company’s shares.

EQS-News: Reduced CAPEX for Zero Carbon Lithium™ Project: Bridging Study

Retrieved on: 
Thursday, December 14, 2023
Carbon, Lithium, Heat, Bev, Geothermal energy, NPV, Electric vehicle, CapeNature, Acquisition, EPC, Tier 1, VUL, CAPEX, FDP, RISK, Policy, Employment, FSE, LCE, LHM, Feed-in tariff, Security (finance), Renewable energy, Recycling, Pharmaceutical industry, Fine chemical, Environmental remediation

Reduced CAPEX for Zero Carbon Lithium™ Project: Bridging Study

Key Points: 
  • Reduced CAPEX for Zero Carbon Lithium™ Project: Bridging Study
    The issuer is solely responsible for the content of this announcement.
  • Reduced CAPEX for Zero Carbon Lithium™ Project:
    First integrated renewable geothermal energy, and lithium hydroxide producer with net zero greenhouse gas emissions.
  • Securing Europe’s lithium supply chain
    Vulcan Energy Resources Limited (Vulcan; ASX: VUL, FSE: VUL, the Company) is pleased to announce the results of its Bridging Engineering Study for Phase One of Vulcan’s Zero Carbon Lithium™ Project.
  • REDUCED RISK: Streamlining into one core production area that is already commercially producing brine, with increased lithium reserves.

EQS-News: Environmental and Social Impact Assessment completed for Phase One ZERO CARBON LITHIUM™ Project

Retrieved on: 
Thursday, December 14, 2023
Carbon, Storm, Heat, ERM, Research, Lithium, New Source Performance Standards, Sustainability, ASX, Lead, International Finance Corporation, ZERO, Equator Principles, VUL, Project, ESIA, Biophysical environment, Social impact assessment, Phase 1, EP4, FSE, Risk management, Renewable energy

Vulcan Energy Resources Limited (Vulcan, ASX: VUL, FSE: VUL, the Company) announces that its Environmental and Social Impact Assessment (ESIA) for Phase One of its Zero Carbon Lithium™ Project (Project) has been completed by ERM.

Key Points: 
  • Vulcan Energy Resources Limited (Vulcan, ASX: VUL, FSE: VUL, the Company) announces that its Environmental and Social Impact Assessment (ESIA) for Phase One of its Zero Carbon Lithium™ Project (Project) has been completed by ERM.
  • Vulcan is advancing Phase One of its ZERO CARBON LITHIUM™ Project: the first integrated project delivering renewable energy and lithium, from Europe for Europe.
  • Key outcomes of the ESIA report:
    The environmental and social baseline, impact assessment, and cumulative impact assessment completed by ERM is in line with lenders’ requirements to ensure a level of environmental performance prior to the furnishing of debt finance, e.g.
  • Vulcan’s ESG Lead, Storm Taylor, commented: “The completion of the Environmental and Social Impact Assessment marks a significant milestone in the advancement of our Zero Carbon Lithium™ Project.

EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, December 14, 2023
Annual general meeting, Food, Fast Track, Ruxolitinib, Conference call, BET, FSE, EZH2, CET, EZH1, JAK, Society, FDA, ASH, Abstract, PST, Patient, Conference, Webcast, ARID1A, Pharmaceutical industry, Cryptocurrency, Video game, Tafasitamab, MorphoSys

“With pelabresib, MorphoSys has the potential to meaningfully improve upon current first-line treatments for patients with myelofibrosis.

Key Points: 
  • “With pelabresib, MorphoSys has the potential to meaningfully improve upon current first-line treatments for patients with myelofibrosis.
  • Minjuvi royalty revenue of € 1.2 million for sales outside of the U.S. in the third quarter 2023 and € 4.1 million for the first nine months of 2023.
  • Events After the End of the Third Quarter of 2023:
    MorphoSys updated its financial guidance for 2023 financial year on October 25, 2023.
  • Total revenues for the third quarter 2023 were € 63.8 million compared to € 95.8 million for the same period in 2022.

EQS-News: Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform

Retrieved on: 
Thursday, December 14, 2023
European Patent Office, Safety, European Patent Convention, Spacecraft, HPHA, ATAC, Amanitin, EPO, Research, Patent, FSE, Gesellschaft mit beschränkter Haftung

Ladenburg, Germany, 15 November 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that its subsidiary Heidelberg Pharma Research GmbH has been granted a patent covering site-specific ATAC conjugates by the European Patent Office (EPO).

Key Points: 
  • Ladenburg, Germany, 15 November 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that its subsidiary Heidelberg Pharma Research GmbH has been granted a patent covering site-specific ATAC conjugates by the European Patent Office (EPO).
  • Site-specific ATAC conjugates comprise a genetically engineered antibody to which Heidelberg Pharma’s proprietary amatoxin payloads can be coupled via specific linkers.
  • The European patent also covers a method for the synthesis of such conjugates as well as their use in the treatment of diseases.
  • Professor Andreas Pahl, Chief Scientific Officer of Heidelberg Pharma, comments: "We are very pleased that this patent has been granted, as it protects essential aspects of our ATAC technology, as e.g.

EQS-News: Heidelberg Pharma AG: Heidelberg Pharma Announces Changes to the Executive Management Board

Retrieved on: 
Wednesday, December 13, 2023
HPHA, Teaching, Research, Chemistry, Research and development, FSE, Supervisory board, ADC, RTÉ Executive Board, Pharmaceutical industry

His successor will be Prof. Dr. Andreas Pahl, Chief Scientific Officer

Key Points: 
  • His successor will be Prof. Dr. Andreas Pahl, Chief Scientific Officer
    Ladenburg, Germany, 29 November 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that Dr. Jan Schmidt-Brand, Chief Executive Officer (CEO) of Heidelberg Pharma AG and Managing Director of the subsidiary Heidelberg Pharma Research GmbH, is planning to retire at the beginning of February 2024 and step down from his positions.
  • Prof. Pahl has been Head of Research & Development at Heidelberg Pharma since 2012 and has been a member of the Executive Board since 2016.
  • Dr. Schmidt-Brand has been with Heidelberg Pharma since 2001, first as Managing Director of the subsidiary Heidelberg Pharma Research GmbH and since 2012 as a member of the Management Board of Heidelberg Pharma AG.
  • Prof. Christof Hettich, Chairman of the Supervisory Board of Heidelberg Pharma AG, commented: "On behalf of the Supervisory Board, I would like to sincerely thank Dr. Schmidt-Brand for his many years of service on the Executive Management Board of Heidelberg Pharma AG.

EQS-News: Elmos: Profitable growth trajectory continues in third quarter of 2023

Retrieved on: 
Tuesday, December 12, 2023
Growth, Sale, Capital, FSE, Elmos Semiconductor, Investment, Capital expenditure, Security (finance), EBIT

Dortmund, November 8, 2023: Elmos Semiconductor SE (FSE: ELG) succeeded in continuing its growth trajectory in the third quarter of 2023.

Key Points: 
  • Dortmund, November 8, 2023: Elmos Semiconductor SE (FSE: ELG) succeeded in continuing its growth trajectory in the third quarter of 2023.
  • Continued growth led to a further rise in EBIT to 41.6 million Euro in the third quarter (Q3 2022: 29.8 million Euro).
  • Adjusted free cash flow stood at 33.9 million Euro in Q3 2023 (Q3 2022: -8.7 million Euro).
  • As a result, Elmos expects a negative operating adjusted free cash flow in 2023 (excluding effects from M&A transactions).

EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023

Retrieved on: 
Sunday, December 10, 2023
Management, Conference, EST, Q&A, GMT, FSE, MorphoSys, CET, Webcast, Clothing, Flour, Video game

Invitation to MorphoSys’ Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023

Key Points: 
  • Invitation to MorphoSys’ Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
    The issuer is solely responsible for the content of this announcement.
  • Invitation to MorphoSys’ Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
    MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the third quarter and first nine months 2023 on November 15, 2023, at 10:00 pm CET (09:00 pm GMT; 04:00 pm EST).
  • MorphoSys' Management team will host a conference call and webcast on November 16, 2023, at 02:00 pm CET (01:00 pm GMT; 08:00 am EST) to present the results for the third quarter and first nine months 2023 and provide an outlook for the remainder of the year.
  • The conference call will start with a presentation by the Management team followed by a Q&A session.